Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI; ELECT Study Investigators. Fisher GA Jr, et al. Among authors: wolin em. Endocr Pract. 2018 Mar;24(3):243-255. doi: 10.4158/EP172000.OR. Endocr Pract. 2018. PMID: 29547049 Clinical Trial.
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group. Fisher GA Jr, et al. Among authors: wolin em. Oncologist. 2018 Jan;23(1):16-24. doi: 10.1634/theoncologist.2017-0284. Epub 2017 Oct 16. Oncologist. 2018. PMID: 29038234 Free PMC article. Clinical Trial.
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Pavel ME, et al. Among authors: wolin em. Oncologist. 2019 Apr;24(4):463-474. doi: 10.1634/theoncologist.2018-0217. Epub 2018 Oct 24. Oncologist. 2019. PMID: 30355775 Free PMC article. Clinical Trial.
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Lombard-Bohas C, et al. Among authors: wolin em. Pancreas. 2015 Mar;44(2):181-9. doi: 10.1097/MPA.0000000000000262. Pancreas. 2015. PMID: 25479584 Free PMC article. Clinical Trial.
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.
Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group. Singh S, et al. Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24. Neuroendocrinology. 2018. PMID: 28554173 Clinical Trial.
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors.
Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC; from the Carcinoid Syndrome Control Collaborative. Eads JR, et al. Among authors: wolin em. Pancreas. 2020 Oct;49(9):1123-1130. doi: 10.1097/MPA.0000000000001658. Pancreas. 2020. PMID: 32991344 Review.
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.
Strosberg JR, Fisher GA, Benson AB, Malin JL; GEPNET Treatment Consensus Panel; Cherepanov D, Broder MS, Anthony LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Strosberg J, Wolin EM. Strosberg JR, et al. Among authors: wolin em. Pancreas. 2013 Apr;42(3):397-404. doi: 10.1097/MPA.0b013e31826d3a17. Pancreas. 2013. PMID: 23211372
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Pavel ME, et al. Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0. Epub 2017 Aug 30. Lancet Oncol. 2017. PMID: 28838862 Clinical Trial.
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.
Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Buzzoni R, et al. Among authors: wolin em. Onco Targets Ther. 2017 Oct 16;10:5013-5030. doi: 10.2147/OTT.S142087. eCollection 2017. Onco Targets Ther. 2017. PMID: 29081664 Free PMC article.
110 results